## **Supplementary Methods**

## **Search Strategy for PubMed**

- 1. (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double blind method [mh] OR single blind method [mh] OR cross-over studies [mh] OR multicenter study [pt]) NOT (animal [mh] NOT human [mh])
- 2. Limit to 2012-12-01 [pdat] to 2012-12-31 [pdat]

## Supplementary Table 1: Full Regression Models for the Association Between Trial Registration and Positive Study Findings

	Overall	Non Industry	Industry
		Funded	Funded
Overall Registration	Adjusted RR (95% CI)	Adjusted RR (95% CI)	Adjusted RR (95% CI)
Any Registration versus not	0.87 (0.79 to	0.75 (0.63 to	1.02 (0.78 to
registered	0.98)	0.89)	1.34)
Funding Source			
Industry versus non-industry	0.99 (0.86 to	-	-
funded	1.14)		
Unclear funding versus non-	1.12 (1.00 to	-	-
industry funded	1.26)		
Sample size (continuous, per 1000	0.99 (0.96 to	0.99 (0.98 to	0.88 (0.71 to
persons)	1.03)	1.02)	1.06)
Random sequence generation	1.05 (0.94 to	1.08 (0.92 to	1.03 (0.81 to
reported versus not reported	1.17)	1.27)	1.32)
Allocation concealment reported	0.93 (0.83 to	0.90 (0.75 to	1.02 (0.79 to
versus not reported	1.05)	1.09)	1.32)
Drug versus non-drug intervention	1.13 (1.01 to	1.04 (0.89 to	1.17 (0.89 to
_	1.26)	1.22)	1.53)
Number of centres			
Single centre	0.99 (0.85 to	1.01 (0.79 to	0.93 (0.67 to
versus multicentre	1.15)	1.28)	1.28)
Unclear versus	1.02 (0.89 to	0.99 (0.79 to	1.16 (0.91 to
multicentre	1.17)	1.24)	1.47)
Stratified by Timing of			
Registration			
Timing of Registration			
Prospective registration versus not	0.87 (0.74 to	0.75 (0.58 to	1.04 (0.76 to
registered	1.02)	0.98)	1.42)
Retrospective registration versus	0.88 (0.77 to	0.75 (0.62 to	1.01 (0.76 to
not registered	0.99)	0.90)	1.34)
Funding Source			
Industry versus non-industry	0.99 (0.86 to	-	-
funded	1.15)		
Unclear funding versus non-	1.12 (1.00 to	-	-
industry funded	1.26)		
Sample size (continuous, per 1000	0.99 (0.96 to	0.99 (0.98 to	0.88 (0.71 to
persons)	1.03)	1.02)	1.06)
Random sequence generation	1.05 (0.94 to	1.08 (0.92 to	1.03 (0.81 to
reported versus not reported	1.17)	1.27)	1.32)
Allocation concealment reported	0.93 (0.83 to	0.90 (0.75 to	1.02 (0.79 to
versus not reported	1.05)	1.09)	1.32)

Drug versus non-drug intervention	1.13 (1.01 to	1.04 (0.89 to	1.17 (0.89 to
	1.26)	1.22)	1.53)
Number of centres			
Mutlicentre	0.99 (0.85 to	1.01 (0.79 to	0.93 (0.67 to
versus single centre	1.15)	1.28)	1.28)
Unclear versus	1.02 (0.89 to	0.99 (0.79 to	1.16 (0.91 to
single centre	1.17)	1.24)	1.47)